# Weight-loss jabs 2026: Cost, comparison and risks of Wegovy, Mounjaro and Ozempic

_By Maurice Lichtenberg · Published 2026-06-14 · Updated 2026-09-23_

In Germany in 2026 a weight-loss jab costs you 172.73 to 277.60 euros a month out of pocket for Wegovy and about 206 to 482 euros for Mounjaro, depending on the dose. Statutory insurance pays none of it, because weight-loss drugs have been excluded as lifestyle drugs under Section 34 SGB V since 2004. The new Wegovy pill costs about the same, and the cheapest approved option is the liraglutide generic Nevolat at about 129 euros a month. Ozempic is listed from about 104 euros but is approved only for type 2 diabetes. Budget for years, not months, because stopping usually brings most of the weight back.

In Germany in 2026, the two most-used jabs approved for weight loss, Wegovy and Mounjaro, cost you roughly 170 to 480 euros a month out of pocket. Statutory health insurance does not pay. Here is what each drug does, what it costs per dose, where the risks are, and why stopping almost always brings the weight back.

## On this page

- What does a weight-loss jab cost in Germany in 2026?
- Ozempic, Wegovy or Mounjaro: What is the difference?
- Which weight-loss jab works best? Mounjaro vs. Wegovy in trials
- What side effects and risks does the weight-loss jab have?
- Who is the weight-loss jab for, and who is it not for?
- Keeping muscle on GLP-1: How do you lose fat instead of muscle?
- What comes next? Weight-loss pills and triple agonists

## What does a weight-loss jab cost in Germany in 2026?

For the two most-used jabs approved for weight loss, Wegovy and Mounjaro, you pay roughly 172 to 482 euros a month out of pocket in 2026, depending on the drug and dose. Statutory health insurance (GKV) covers none of it when the goal is weight loss. That is the most important and most misunderstood point. The prices here are pharmacy retail prices: Wegovy as of September 2026, the other drugs as of March 2026. [1, 2, 7]

Shopping around does not help much: prescription-only drugs in Germany have a fixed pharmacy price under the drug price ordinance (Arzneimittelpreisverordnung, AMPreisV). That applies on a private prescription and at German online pharmacies too. Small differences between sources usually come from price changes over time. [30]

**Wegovy (semaglutide) as a pen** costs 172.73 euros for the starting doses 0.25, 0.5 and 1.0 mg, 237.14 euros for 1.7 mg and 277.60 euros for the 2.4 mg maintenance dose. One pen lasts four weeks. [1, 2, 7]

**Wegovy as a pill (oral semaglutide)** has been sold in German pharmacies since 1 September 2026. You take it once a day instead of injecting once a week. It is not cheaper: 30 tablets of 1.5 mg or 4 mg cost 172.73 euros each, and 9 mg costs 233.23 euros. The price of the 25 mg maintenance dose was not yet listed at launch. [7] You take the pill on an empty stomach right after waking up, with a sip of water. Then you wait 30 minutes before eating, drinking or taking other medicines. [7] Insurance pays nothing here either. [3]

| Wegovy dose | Form | Price per pack |
|---|---|---|
| 0.25 / 0.5 / 1.0 mg | Pen, 4 weeks | 172.73 euros [7] |
| 1.7 mg | Pen, 4 weeks | 237.14 euros [7] |
| 2.4 mg | Pen, 4 weeks | 277.60 euros [7] |
| 1.5 / 4 mg | Pill, 30 tablets | 172.73 euros [7] |
| 9 mg | Pill, 30 tablets | 233.23 euros [7] |
| 25 mg | Pill, 30 tablets | not yet listed at launch [7] |

**Mounjaro (tirzepatide)** costs about 206 to 482 euros a month depending on dose and pack size: about 206 euros to start on 2.5 mg, about 375 euros on a typical maintenance dose and up to about 482 euros on the highest dose. [1]

**Nevolat (liraglutide)** is the cheapest drug approved for weight loss. The generic from Zentiva has been in pharmacies since December 2025. It costs about 79 euros to start and about 129 euros a month on maintenance. [1, 31] The catch: you inject liraglutide every day, and it works less strongly on average than semaglutide or tirzepatide. The original brand Saxenda costs about 285 euros a month. [1]

**Ozempic (semaglutide)** is listed cheaply at around 104 to 200 euros a month. But careful: Ozempic is approved only for type 2 diabetes. Using it to lose weight is off-label (outside the approval). More on that below, because cheap does not mean harmless here.

Why doesn't insurance pay? Because German law has excluded weight-loss medicines since 2004. They count as so-called lifestyle drugs under Section 34 (1) sentences 7 and 8 of SGB V (the German Social Code, Book Five). [3, 4] For Wegovy, the Federal Joint Committee (G-BA, the top self-governance body that decides what statutory insurance covers) made this formal on 21 March 2024. It added Wegovy to Annex II of its medicines directive, the list of excluded lifestyle drugs. The decision took effect on 15 June 2024. [4]

A clear note is worth making here, because the opposite is circulating online: some sources claim insurance will reimburse the weight-loss jab from 15 June 2026. That is not true. 15 June 2024 was the day the exclusion became binding. That is the opposite of a reimbursement start. There is no date from which the GKV pays for the weight-loss jab for weight regulation.

As of September 2026 there is political debate. The new G-BA chair has floated coverage for severe obesity. The head of the AOK federal association counters that treating everyone insured with a BMI of 30 or more would cost about 45 billion euros a year, and about 14 billion from a BMI of 35. There is no bill, though, so insurance still pays nothing. [5]

This holds even in the extreme case. Even with a very high BMI (over 40) plus comorbidities there is no entitlement to coverage, and the G-BA has no discretion here. [3, 4] Courts agree. Most recently the Lower Saxony-Bremen state social court (LSG Niedersachsen-Bremen, L 16 KR 161/26 B ER, 28 April 2026) turned down Mounjaro in urgent proceedings for a 24-year-old woman with a hormonal disorder and obesity. The law leaves no room for case-by-case exceptions, the court said. [6]

There is one exception: the diabetes indication. Ozempic and Rybelsus (semaglutide for type 2 diabetes) remain reimbursable for diabetics, because the lifestyle exclusion applies only when the approved indication is weight regulation. [4, 5]

On supply: availability is much easier than in previous years, and most doses are in stock. Single strengths can still run short: at the pill's launch, for example, the 25 mg dose was missing. If in doubt, ask your pharmacy first. [7]

One budgeting catch the marketing likes to skip: the monthly price is not the whole bill. Stopping typically brings the weight back (more on that below), so in practice this is a long-term therapy. One pen lasts four weeks, so a year takes 13 packs. Budget for the pack price times 13, times potentially many years. [23]

| Drug | Active ingredient | Approval DE/EU | Out of pocket per month 2026 | GKV for obesity? |
|---|---|---|---|---|
| Wegovy (pen) | Semaglutide (weekly) | Obesity (weight management) | 172.73 to 277.60 euros [1, 2, 7] | No, Section 34 SGB V, G-BA Annex II [3, 4] |
| Wegovy (pill) | Semaglutide (oral, daily) | Obesity (EU since July 2026) | from 172.73 euros [7] | No, Section 34 SGB V [3, 4] |
| Mounjaro | Tirzepatide (weekly) | Obesity and type 2 diabetes (EU) | approx. 206 to 482 euros [1] | No for obesity; diabetes prescription only [4, 5, 6] |
| Nevolat | Liraglutide (daily) | Obesity (generic) | approx. 79 to 129 euros [1, 31] | No, Section 34 SGB V [3] |
| Ozempic | Semaglutide | Type 2 diabetes only | approx. 104 to 200 euros [1] | Only as diabetes therapy; weight loss is off-label [1, 4] |

- Out-of-pocket cost 2026: Wegovy 172.73 to 277.60 euros, Mounjaro approx. 206 to 482 euros, Nevolat approx. 129 euros, Ozempic (off-label) approx. 104 to 200 euros per month, depending on dose [1, 2, 7, 31].
- The Wegovy pill has been in German pharmacies since 1 September 2026 and costs about the same as the pen [7].
- Prescription drug prices are fixed by the drug price ordinance, so the same pack costs the same in every German pharmacy [30].
- The GKV has not paid for weight-loss drugs since 2004 (lifestyle exclusion under Section 34 SGB V). For Wegovy, the G-BA exclusion took effect on 15 June 2024 [3, 4].
- 15 June 2024 was the day the coverage exclusion took effect, not a reimbursement start. As of September 2026 there is political debate but no bill [4, 5].
- There is no entitlement even with a very high BMI and comorbidities [3]; in April 2026 the LSG Niedersachsen-Bremen (L 16 KR 161/26 B ER) turned down Mounjaro for a 24-year-old with a hormonal disorder and obesity, with no room for case-by-case exceptions [6].
- Ozempic and Rybelsus remain reimbursable only for type 2 diabetics, because the diabetes indication is approved there [4, 5].

## Ozempic, Wegovy or Mounjaro: What is the difference?

Three brand names, two active ingredients. One of them works more strongly on average. Ozempic and Wegovy both contain semaglutide, Mounjaro contains tirzepatide. The difference lies in the mechanism, the approval and the dosing.

**Semaglutide** (in Ozempic and Wegovy) is a pure GLP-1 receptor agonist. GLP-1 is a natural gut hormone released after eating. The drug mimics it: it slows gastric emptying, boosts the feeling of fullness, dampens appetite and promotes glucose-dependent insulin release. [8]

**Tirzepatide** (in Mounjaro) is a dual agonist: it acts on both the GIP and the GLP-1 receptor at the same time. GIP is a second gut hormone that also influences metabolism. This double action explains why tirzepatide tends to act more strongly on weight and blood sugar. [8, 9]

The brand names sort out like this: semaglutide is called **Ozempic** (diabetes) and **Wegovy** (obesity). Tirzepatide is called **Mounjaro** in the EU (approved for both). In the US it also sells as **Zepbound** (the brand name for weight loss there). [8]

The approval is the decisive everyday difference: Wegovy and Mounjaro are approved in the EU for weight management. Ozempic is approved only for type 2 diabetes, so any use for weight loss is off-label. Off-label does not automatically mean dangerous, but it worsens supply shortages for diabetics who need the drug medically. That is why Ozempic should not be promoted as a cheap weight-loss alternative. [4, 8, 1]

Both drugs are dosed up slowly (titration) so the gastrointestinal tract can adapt. **Wegovy** is stepped up over 16 weeks, as one injection under the skin once a week [10, 11]:

- Weeks 1 to 4: 0.25 mg
- Weeks 5 to 8: 0.5 mg
- Weeks 9 to 12: 1.0 mg
- Weeks 13 to 16: 1.7 mg
- From week 17: 2.4 mg, the standard maintenance dose

Since February 2026 the EU also allows a higher 7.2 mg dose for adults who started with a BMI of 30 or more, after at least four weeks on 2.4 mg. A dedicated 7.2 mg pen was approved in the EU in July 2026, but we found no German price for it as of September 2026, so don't count on it yet. [11]

The **Wegovy pill** starts at 1.5 mg a day and steps up every four weeks through 4 and 9 mg to the 25 mg maintenance dose. [7]

**Mounjaro** starts at 2.5 mg and steps up every four weeks (2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg). Available maintenance doses are 5, 10 and 15 mg, the maximum dose is 15 mg once a week under the skin. [12, 13]

- Three brands, two active ingredients: Ozempic and Wegovy contain semaglutide, Mounjaro contains tirzepatide [8].
- Semaglutide is a pure GLP-1 agonist; tirzepatide also acts on the GIP receptor and is therefore on average stronger [8, 9].
- Wegovy and Mounjaro are approved for weight loss, Ozempic only for type 2 diabetes; using Ozempic to lose weight is off-label [4, 8].
- Wegovy is titrated over 16 weeks to the maintenance dose 2.4 mg; since February 2026 the EU also allows 7.2 mg for some adults [10, 11].
- The Wegovy pill is taken daily and stepped up every four weeks from 1.5 mg to 25 mg [7].
- Mounjaro starts at 2.5 mg and steps up every four weeks to the maximum dose of 15 mg per week [12, 13].

## Which weight-loss jab works best? Mounjaro vs. Wegovy in trials

Head to head, Mounjaro works more strongly: in SURMOUNT-5 people on tirzepatide lost 20.2 percent of their weight on average over 72 weeks, on semaglutide (Wegovy) 13.7 percent. [9] In its own approval trial, tirzepatide led to an average loss of roughly 15 to 21 percent of body weight, far more than placebo. These are not marketing figures but results from large randomized trials (RCTs, the gold standard, where chance decides who gets the drug and who gets a dummy).

The central trial is **SURMOUNT-1 (NEJM 2022, Jastreboff et al.)**, a phase 3 study in adults with obesity or overweight without diabetes over 72 weeks. Mean weight loss was minus 15.0 percent on 5 mg tirzepatide, minus 19.5 percent on 10 mg and minus 20.9 percent on 15 mg, versus minus 3.1 percent on placebo. [14, 15] Included were people with a BMI of 30 or higher, or BMI 27 or higher with at least one weight-related complication. [14]

You may see higher numbers elsewhere. That is not a contradiction. The figures here count everyone who started the trial, whether or not they kept injecting (researchers call this the treatment-regimen estimand). Manufacturers and the press often quote the more optimistic figure, up to about 22.5 percent, which only counts people who stuck strictly to the drug. [14] Both numbers are real. They measure different things, so don't mix them.

The share of strong responders was high too. In SURMOUNT-1, at least 20 percent of body weight was lost by 30.0 percent (5 mg), 50.1 percent (10 mg) and 56.7 percent (15 mg) of those treated. [15] So more than half the people on the top dose lost a fifth of their body weight or more.

For comparison with semaglutide: in **STEP-1 (NEJM 2021, Wilding et al.)** semaglutide 2.4 mg led to minus 14.9 percent after 68 weeks versus minus 2.4 percent on placebo, and 86 percent reached at least 5 percent weight loss. [16]

The head-to-head comes from **SURMOUNT-5 (NEJM 2025, Aronne et al.)**: tirzepatide versus semaglutide directly, 72 weeks, 751 participants without diabetes. Tirzepatide reached minus 20.2 percent, semaglutide minus 13.7 percent, an advantage of about 6.5 percentage points for tirzepatide. [9]

On blood sugar, too, tirzepatide leads. In **SURPASS-2 (NEJM 2021, Frias et al.)** in type 2 diabetes, tirzepatide 15 mg lowered HbA1c (the long-term blood sugar value of the past weeks) over 40 weeks by 2.30 percentage points, semaglutide 1 mg by 1.86 percentage points. [17]

Important for the full picture: these percentages apply to the trial period under medical supervision and as an addition to diet and exercise. They say nothing about what happens after stopping. That is exactly what we look at below.

- SURMOUNT-1 (NEJM 2022): tirzepatide led to minus 15.0 to minus 20.9 percent weight over 72 weeks vs. minus 3.1 percent on placebo [14, 15].
- More than half the people on 15 mg tirzepatide (56.7 percent) lost at least 20 percent of their weight [15].
- STEP-1 (NEJM 2021): semaglutide 2.4 mg reached minus 14.9 percent after 68 weeks, 86 percent lost at least 5 percent [16].
- SURMOUNT-5 (NEJM 2025): head-to-head, tirzepatide (minus 20.2 percent) beat semaglutide (minus 13.7 percent) by about 6.5 percentage points [9].
- SURPASS-2 (NEJM 2021): in type 2 diabetes, tirzepatide lowered HbA1c more than semaglutide (minus 2.30 vs. minus 1.86 percentage points) [17].

## What side effects and risks does the weight-loss jab have?

By far the most common side effects are gastrointestinal complaints, usually mild to moderate and mostly during titration. Alongside that there are a few rarer but more serious risks and a few myths that cause more fear than the data warrant.

**Gastrointestinal.** Your gut takes most of the hit, mainly while the dose is still being stepped up. This is what people on tirzepatide 5 / 10 / 15 mg reported in SURMOUNT-1 [14]:

- Nausea: 24.6 / 33.3 / 31.0 percent (placebo 9.5 percent)
- Diarrhea: 18.7 / 21.2 / 23.0 percent (placebo 7.3 percent)
- Constipation: 16.8 / 17.1 / 11.7 percent
- Vomiting: 8.3 / 10.7 / 12.2 percent
- Stopped because of side effects: 4.3 / 7.1 / 6.2 percent (placebo 2.6 percent)

Most complaints ease over time.

**Gallbladder.** This risk is real. A meta-analysis of 76 RCTs with 103,371 patients (He et al., JAMA Intern Med 2022) found these relative risks (RR; 1.0 would mean no change) [18]:

- Gallstones: RR 1.27
- Gallbladder inflammation: RR 1.36
- Biliary disease: RR 1.55
- In the trials for weight loss: RR 2.29, more than double the risk of the comparison groups

The risk also rose with higher doses and longer use. [18] Rapid weight loss makes gallstones more likely anyway. The drug adds to that.

**Pancreas (pancreatitis).** The data are mixed and the signal is small. A meta-analysis of 62 RCTs with 66,232 patients (Wen et al. 2025) found [19]:

- Pancreatitis overall: a modest but statistically significant rise, relative risk (RR) 1.44. That means a 44 percent higher risk than in the comparison groups (95 percent confidence interval 1.09 to 1.89; p=0.009).
- Once the trials were split by background medication (the other drugs patients were already taking): RR 1.28 and 1.37, neither significant.
- Pancreatic cancer: not raised overall, RR 1.30 (95 percent CI 0.86 to 1.97).

The warning stays in the package insert as a precaution. If you have had pancreatitis before, the EU label asks for particular caution. [11, 13, 19]

**Thyroid.** There is a lot of fear-mongering here, so to be clear: semaglutide and tirzepatide caused dose- and time-dependent thyroid C-cell tumors in rodent studies. In the US the labels therefore rule them out if you or close family have had medullary thyroid carcinoma (MTC) or MEN-2 syndrome. The EU labels that apply in Germany list no such contraindication, but many doctors still hold back in that situation. Whether the rodent finding carries over to humans is unclear. A Scandinavian cohort of about 145,000 users found no clear rise in thyroid cancer. [26] A French case-control study linked 1 to 3 years of use to more thyroid cancer, including MTC. [27] So there is no proof that the jab causes thyroid cancer, and no full all-clear either. [20, 26, 27]

**Eyes, stomach, surgery.** The EU label also warns about rarer problems. Studies show a higher risk of NAION on semaglutide, a sudden loss of vision from poor blood flow to the optic nerve. If your vision suddenly drops, see an eye doctor straight away. With severe gastroparesis (a stomach that empties extremely slowly), semaglutide is not recommended. And tell your anaesthetist about the jab before any operation or sedation, because food stays in the stomach longer. [11, 13]

**Muscle loss.** A substantial part of the weight lost is not fat but lean mass. That is important enough for its own section, see [keeping muscle on GLP-1](/en/guide/glp1-muskelerhalt) below. [21]

**Ozempic face.** Sunken cheeks and temples, looser skin: this is a consequence of rapid weight loss, namely the shrinking of the facial fat pads while skin elasticity lags behind. It is not a direct drug effect, it happens with any fast weight loss. This explanation comes from dermatology explainers, not controlled trials, but it is considered plausible. [22]

- Gastrointestinal complaints are the most common side effect: in SURMOUNT-1 nausea in up to 33 percent, mostly mild and mainly during titration [14].
- Gallbladder risk is genuinely raised: a meta-analysis of 103,371 patients shows RR 1.27 to 1.55, and RR 2.29 in the weight-loss trials [18].
- Pancreatitis: a 2025 meta-analysis (62 RCTs, 66,232 patients) found a modest rise (RR 1.44; 95 percent CI 1.09 to 1.89) that lost significance once split by background medication. Pancreatic cancer was not raised (RR 1.30). The warning stays as a precaution [19].
- Thyroid: C-cell tumors are proven only in rodents; human data are mixed (no clear rise in a Scandinavian cohort, higher risk after 1 to 3 years in a French study); the MTC/MEN-2 contraindication is US label wording [20, 26, 27].
- The EU label also warns about NAION (sudden vision loss) on semaglutide, severe gastroparesis and aspiration during anaesthesia [11, 13].
- Ozempic face is a consequence of rapid weight loss (fat-pad shrinkage), not a direct drug effect [22].

## Who is the weight-loss jab for, and who is it not for?

The weight-loss jab is a medical obesity therapy, not a beauty tool for the last few kilos. The approval draws the line clearly and explicitly requires a lifestyle program alongside it.

The EMA (European Medicines Agency) approves Wegovy and Mounjaro for adults in one of two groups [10, 12]:

- BMI 30 or higher (obesity)
- BMI 27 to under 30 (overweight) plus at least one weight-related condition, such as high blood pressure, a lipid disorder, sleep apnea, cardiovascular disease or prediabetes

In both cases the jab is an add-on to a calorie-reduced diet and more exercise.

For minor, cosmetic weight loss, by contrast, the jab is not intended. Anyone with a normal BMI who wants to drop a few kilos does not fall under the indication, and the benefit-risk balance then shifts unfavorably. [10, 12]

Not during pregnancy either: both labels advise against it. If you plan a pregnancy, the labels say to stop Wegovy at least 2 months ahead and Mounjaro at least 1 month ahead. [11, 13]

The part the marketing often leaves out: the jab does not replace diet and exercise. The approval explicitly requires it as an add-on to fewer calories and more movement. [10, 12] To plan your calorie deficit, our [calorie calculator](/en/tools/calorie-calculator) works out your daily needs and target. Anyone who doesn't touch their diet at all gives away part of the effect and part of muscle preservation. A much gentler, weaker-evidence lever on satiety is fiber, covered in detail in the guide on [fiber and fibermaxxing](/en/guide/ballaststoffe-fibermaxxing). And anyone looking for a plant-based alternative without a prescription should know that [berberine as a natural Ozempic](/en/guide/berberin-natuerliches-ozempic) is discussed but is nowhere near the league of prescription GLP-1 drugs. Don't confuse the two.

The most important point for any cost-benefit calculation comes last, and it is uncomfortable: the weight regain after stopping. In the **STEP-1 extension (Wilding et al., Diabetes Obes Metab 2022)**, after stopping semaglutide plus lifestyle, participants regained about two thirds of the weight they had lost (plus 11.6 percentage points over 52 weeks). One year after the end of therapy the net weight loss was only minus 5.6 percent compared with the study start, instead of the minus 17.3 percent during therapy. [23]

So in practice this is a long-term therapy: stopping typically leads to regain. Build that into the decision to start and into your cost plan, because it turns a monthly price into a long-term commitment. [23]

- EMA indication: BMI of 30 or higher, or BMI 27 or higher plus at least one weight-related comorbidity, always as an addition to diet and exercise [10, 12].
- Not intended for cosmetic or minor weight loss; with a normal BMI the benefit-risk balance shifts unfavorably [10, 12].
- Not during pregnancy: the labels say to stop Wegovy at least 2 months and Mounjaro at least 1 month before a planned pregnancy [11, 13].
- The approval explicitly requires a lifestyle program; the jab does not replace diet and exercise [10, 12].
- STEP-1 extension (2022): after stopping, about two thirds of the lost weight came back, leaving only minus 5.6 percent net after one year [23].
- In practice a long-term therapy: stopping triggers regain, which changes the cost-benefit calculation massively [23].

## Keeping muscle on GLP-1: How do you lose fat instead of muscle?

A large part of the weight loss on GLP-1 is not fat but lean mass, meaning muscle and other fat-free tissue. In recent studies this lean-mass loss made up about 25 to 40 percent of total weight loss. [21, 24] That sounds alarming. It gets a lot less scary once you see the context and push back against it.

The range depends on the drug and the measurement. In the DXA subset of STEP-1 (semaglutide) about a third to 40 percent of the loss was lean mass, in the DXA subset of SURMOUNT-1 (tirzepatide) about 25 percent. [21, 24] DXA is a body scan that measures fat and lean mass separately. In SURMOUNT-1 the split was the same on placebo: about three quarters fat, one quarter lean mass. [24] These individual figures are secondarily derived, so read them as a rough range of about a quarter to 40 percent, not as exact values.

Some context before you panic: any fast weight loss costs some lean mass. Even a diet with no drug at all takes some muscle with it. [21, 24] So the question is not whether you lose some, but how to keep the loss small.

The standard advice from obesity and nutrition societies is strength training with progressive resistance (slowly adding load over time) plus enough protein. [28] In one case series (a few patients described in detail, with no control group), three people lifted weights three to five times a week and ate a lot of protein (1.6 to 2.3 g per kg of fat-free mass). Some kept their lean mass or even gained a little. [21] A case series of three people is a hint, not proof. A 2025 advisory from US obesity and nutrition societies mentions targets of about 1.2 to 1.6 g of protein per kg of body weight a day during weight loss, but says there is no consensus yet. With a lot of body fat, using your actual weight can overstate the need. [28]

How exactly you should time protein and training, what protein amounts are realistic and what to watch for in blood work is covered in detail in the dedicated guide on [keeping muscle on GLP-1](/en/guide/glp1-muskelerhalt). The short version here: anyone who loses weight without strength training and without minding protein gives away part of their muscle. That muscle is exactly what you need long term for metabolism and independence in old age.

- About 25 to 40 percent of the weight loss on GLP-1 is lean mass, not fat [21, 24].
- In the DXA subset of STEP-1 (semaglutide) it was about a third to 40 percent, in SURMOUNT-1 (tirzepatide) about 25 percent, the same split as on placebo [21, 24].
- Lean-mass loss is largely normal with rapid weight loss, even without a drug; the only question is how to keep it small [21, 24].
- Strength training plus enough protein is the recommended countermeasure; in a small case series lean mass was partly maintained [21, 28].
- Proposed target, not yet consensus: about 1.2 to 1.6 g of protein per kg of body weight a day while losing weight, combined with regular strength training [28].

## What comes next? Weight-loss pills and triple agonists

The next generation is already in trials, and so far it works even more strongly. The most important drug is called retatrutide (trial code LY3437943), a triple agonist: it acts on the GIP, GLP-1 and glucagon receptors at the same time, so three levers instead of one or two. [25]

The **phase 2 trial (NEJM 2023, Jastreboff et al.)** ran for 48 weeks. On the highest dose (12 mg), people lost 24.2 percent of their body weight on average, and on 8 mg 22.8 percent. On placebo it was 2.1 percent. [25] The side-effect profile is class-typical, mainly nausea, vomiting and diarrhea. [25]

Since then the first phase 3 results are in. In July 2026 Lilly reported weight loss of up to 22.6 percent over 80 weeks in two larger trials, and it plans to file for US approval in early 2027. These figures come from a company press release, not yet from a peer-reviewed paper. [29]

Pills are arriving in parallel. The Wegovy pill has been available in Germany since September 2026 (see the cost section above). [7] Lilly's orforglipron, another weight-loss pill, is not approved in the EU as of September 2026.

Before you get your hopes up: retatrutide is not yet approved in the EU, and the US filing is only planned for 2027. [29] You cannot get it prescribed in Germany. Anything that shows up online as a source belongs to the grey market, which this guide deliberately does not cover. See the triple agonists as an exciting outlook, not an option for 2026.

- Retatrutide (LY3437943) is a triple agonist (GIP, GLP-1 and glucagon) and thus the next generation of active ingredients [25].
- Phase 2 trial (NEJM 2023): minus 24.2 percent weight at 12 mg over 48 weeks, vs. minus 2.1 percent on placebo [25].
- The side-effect profile is class-typical gastrointestinal, meaning nausea, vomiting and diarrhea [25].
- Lilly reported phase 3 results in July 2026 (up to 22.6 percent over 80 weeks, press release) and plans a US filing in 2027 [29].
- The Wegovy pill has been on sale in Germany since September 2026 [7].
- Retatrutide is not yet approved in the EU and cannot be prescribed; it is an outlook, not an option for 2026 [25, 29].


## FAQ

### What does the weight-loss jab cost per month in Germany in 2026?

Out of pocket, depending on the drug and dose: Wegovy 172.73 to 277.60 euros per four-week pen, Mounjaro around 206 to 482 euros, Ozempic (off-label) around 104 to 200 euros [1, 2, 7]. The price is fixed by Germany's drug price ordinance, so it is the same in every German pharmacy [30]. Budget for 13 packs a year, times several years, because stopping usually brings the weight back [23].

### Does statutory health insurance (AOK, TK, Barmer) pay for the weight-loss jab?

No, not for weight loss. Medicines for weight regulation have been excluded since 2004 as lifestyle drugs under Section 34 SGB V. That binds every statutory insurer equally, whether AOK, TK or Barmer. For Wegovy, the G-BA exclusion took effect on 15 June 2024 [3, 4]. Even with a very high BMI plus comorbidities there is no entitlement [3], and courts see no room for case-by-case exceptions [6]. Only the diabetes indication (Ozempic, Rybelsus for type 2 diabetes) remains reimbursable [4, 5].

### Is it true that insurance reimburses the weight-loss jab from 15 June 2026?

No, that is a mix-up. 15 June 2024 (not 2026) was the day the coverage exclusion for Wegovy took effect, which is the opposite of a reimbursement start [4]. There is no date from which the GKV pays for the weight-loss jab for weight regulation.

### Which is stronger, Mounjaro or Wegovy?

Head-to-head, Mounjaro (tirzepatide). In SURMOUNT-5 (NEJM 2025), participants on tirzepatide lost minus 20.2 percent over 72 weeks, on semaglutide minus 13.7 percent, an advantage of about 6.5 percentage points [9]. Tirzepatide acts on the GIP and GLP-1 receptors at once, semaglutide only on the GLP-1 receptor [8].

### Can I take Ozempic to lose weight because it is cheaper?

Ozempic is listed cheaper at around 104 to 200 euros a month, but it is approved only for type 2 diabetes. Using it for weight loss is off-label [1, 4]. That worsens supply shortages for diabetics who need the drug medically. For weight management, Wegovy, Mounjaro and liraglutide (Saxenda, Nevolat) are the approved drugs, and the choice belongs in medical hands.

### Does the weight-loss jab cause thyroid cancer?

The human data are mixed. C-cell tumors are proven only in rodent studies. A large Scandinavian cohort found no clear rise in thyroid cancer [26], while a French study found a higher risk after 1 to 3 years of use, including medullary thyroid carcinoma (MTC) [27]. There is no proof of a causal link, but no full all-clear either. If you or close family have had MTC or MEN-2, talk to your doctor before starting [20].

### What happens when I stop the weight-loss jab again?

There is no fixed end date: the jab works only while you take it. Typically a large part of the weight comes back after stopping. In the STEP-1 extension, participants regained about two thirds of the weight they had lost, leaving only minus 5.6 percent net after one year instead of minus 17.3 percent during therapy [23]. In practice the treatment is therefore a long-term therapy.

### Do I lose muscle instead of fat with the weight-loss jab?

Part of the loss is lean mass: in recent studies about 25 to 40 percent of the weight loss [21, 24]. That is largely normal with rapid weight loss, even without a drug. Strength training and enough protein are the recommended way to limit it; a 2025 advisory mentions proposed targets of about 1.2 to 1.6 g of protein per kg of body weight a day while losing weight [28]. More on that in the muscle-preservation guide.

### What does the Wegovy weight-loss pill cost in Germany?

About the same as the jab: 172.73 euros for 30 tablets of 1.5 mg or 4 mg, and 233.23 euros for 9 mg. The price of the 25 mg maintenance dose was not yet listed at the 1 September 2026 launch [7]. You need a prescription, and statutory insurance does not pay for the pill for weight loss [3, 4].

### Which weight-loss jab is the cheapest in Germany?

The cheapest drug approved for weight loss is Nevolat, a generic liraglutide from Zentiva, in pharmacies since December 2025: about 79 euros to start and about 129 euros a month on maintenance [1, 31]. You inject liraglutide daily, and it works less strongly on average than semaglutide or tirzepatide. The only other options under 200 euros are the Wegovy starter doses and the low pill doses at 172.73 euros each [7]. Ozempic is listed cheaper but is not approved for weight loss [1, 4].

### How much does the weight-loss jab cost per year?

One pen lasts four weeks, so a year takes 13 packs. On the Wegovy 2.4 mg maintenance dose that is about 3,600 euros a year (13 times 277.60 euros) [7]. Mounjaro costs about 375 euros per pack on a typical maintenance dose [1], so about 4,900 euros a year. The first months cost less because the low doses are cheaper. Since about two thirds of the lost weight usually returns after stopping [23], plan for several years, not one.

## Sources

- apodiscounter (Ratgeber Abnehmen). (2026). Abnehmspritze Kosten 2026. apodiscounter.de. https://www.apodiscounter.de/ratgeber/abnehmen/abnehmspritze/kosten
- fitfursleben.de. (2026). Wegovy Preis 2026 in Deutschland: Kosten pro Monat ab 172 Euro. fitfursleben.de. https://www.fitfursleben.de/wegovy/preis
- Sozialgesetzbuch Fuenftes Buch (SGB V). (2024). Paragraf 34 SGB V: Ausgeschlossene Arznei-, Heil- und Hilfsmittel. dejure.org. https://dejure.org/gesetze/SGB_V/34.html
- Gemeinsamer Bundesausschuss (G-BA). (2024). G-BA vollzieht den gesetzlichen Verordnungsausschluss fuer das Abmagerungsmittel Wegovy nach. g-ba.de. https://www.g-ba.de/presse/pressemitteilungen-meldungen/1170/
- Pharmazeutische Zeitung (dpa). (2026). Abnehmspritze würde Kassen Milliarden kosten. pharmazeutische-zeitung.de. https://www.pharmazeutische-zeitung.de/abnehmspritze-wuerde-kassen-milliarden-kosten-167819/
- Rechtslupe (Redaktion). (2026). Abnehmspritze ist nur ein Lifestyle-Medikament (LSG Niedersachsen-Bremen, Beschluss vom 28.04.2026, L 16 KR 161/26 B ER). rechtslupe.de. https://www.rechtslupe.de/sozialrecht/abnehmspritze-ist-nur-ein-lifestyle-medikament-3349716
- APOTHEKE ADHOC (Redaktion). (2026). Das kostet die Abnehmpille. apotheke-adhoc.de. https://www.apotheke-adhoc.de/nachrichten/detail/pharmazie/das-kostet-die-abnehmpille/
- Fahim SA, Attia YM, Messiha A, et al. (2025). Comparative safety and side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2025.118731
- Aronne LJ, et al.; SURMOUNT-5 Investigators. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2416394
- Novo Nordisk / European Medicines Agency (EMA). (2024). Wegovy (semaglutide) Summary of Product Characteristics / EPAR Product Information. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
- European Medicines Agency (EMA). (2024). Wegovy EPAR Product Information (dose-escalation table and 2.4 mg maintenance dose). European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf
- European Medicines Agency (EMA) / Eli Lilly. (2024). Mounjaro (tirzepatide) EPAR / Product Information. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro
- European Medicines Agency (EMA). (2026). Mounjaro (tirzepatide) EPAR Product Information (SmPC, including section 4.2 posology). European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf
- Jastreboff AM, et al.; SURMOUNT-1 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2206038
- Liu L, Shi H, Xie M, et al. (2024). Efficacy and safety of tirzepatide versus placebo in overweight or obese adults without diabetes: a systematic review and meta-analysis of randomized controlled trials. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-024-01779-x
- Wilding JPH, et al.; STEP 1 Study Group. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2032183
- Frias JP, et al.; SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2107519
- He L, et al. (2022). Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2022.0338
- Wen J, et al. (2025). Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70113
- U.S. Food and Drug Administration (FDA). (2025). Thyroid C-cell tumor (MTC/MEN2) boxed-warning basis: FDA prescribing labels for Ozempic and Mounjaro plus thyroid-risk reviews. accessdata.fda.gov. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
- Tinsley GM, Nadolsky S. (2025). Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: a case series. SAGE Open Medical Case Reports. https://doi.org/10.1177/2050313X251388724
- Cleveland Clinic Health Essentials. (2024). Ozempic Face: facial volume loss from rapid weight loss (clinical explainer). health.clevelandclinic.org. https://health.clevelandclinic.org/ozempic-face
- Wilding JPH, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14725
- Look M, Dunn JP, Kushner RF, et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16275
- Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2301972
- Pasternak B, Wintzell V, Hviid A, et al. (2024). Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. https://doi.org/10.1136/bmj-2023-078225
- Bezin J, Gouverneur A, Penichon M, et al. (2023). GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care. https://doi.org/10.2337/dc22-1148
- Mozaffarian D, Agarwal M, Aggarwal M, et al. (2025). Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). https://doi.org/10.1002/oby.24336
- Eli Lilly and Company. (2026). Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C (manufacturer press release). PR Newswire. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-successful-in-two-additional-phase-3-obesity-trials-delivering-significant-improvements-in-weight-and-a1c-302832674.html
- Bundesministerium der Justiz. (2026). Arzneimittelpreisverordnung (AMPreisV). gesetze-im-internet.de. https://www.gesetze-im-internet.de/ampreisv/
- APOTHEKE ADHOC (Redaktion). (2025). Nevolat: Neue Abnehmspritze ab Dezember. apotheke-adhoc.de. https://www.apotheke-adhoc.de/nachrichten/detail/markt/nevolat-neue-abnehmspritze-ab-dezember/

_Full guide: https://longevity-germany.com/en/guide/abnehmspritze-kosten-vergleich_

---

_Canonical: https://longevity-germany.com/en/guide/abnehmspritze-kosten-vergleich · Part of Longevity Cities · Updated 2026-09-23_